Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells

Examination of the expanding pathways for the regulation of p21 expression and activity

(2010) Yong-Sam Jung et al.   CELLULAR SIGNALLING

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

(2009) Kristie A. Blum et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications

(2009) D. S. Schrump   CLINICAL CANCER RESEARCH

Expression of Hypoxia-Inducible Factor-1α, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma

(2009) Kotaro Miyake et al.   PANCREAS

Anoikis: A necessary death program for anchorage-dependent cells

(2008) Paola Chiarugi et al.   BIOCHEMICAL PHARMACOLOGY

SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103)

(2008) Stéphane Raeppel et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Sp1-Mediated TRAIL Induction in Chemosensitization

(2008) J. Xu et al.   CANCER RESEARCH

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

(2008) C. Bonfils et al.   CLINICAL CANCER RESEARCH

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

(2008) Lillian L. Siu et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery ofN-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor

(2008) Nancy Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

(2008) M. Fournel et al.   MOLECULAR CANCER THERAPEUTICS